Efficacy of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel versus Conventional Dose Doxorubicin, Cyclophosphamide Followed by Paclitaxel or Docetaxel in Patients with Node-Positive Breast Cancer

Yazilitas, Dogan; Sendur, Mehmet Ali Nahit; Karaca, Halit; Ozdemir, Nuriye; Aksoy, Sercan; Berk, Veli; Yazici, Ozan; Ozturk, Banu; Ozkan, Metin; Zengin, Nurullah; Altundag, Kadri

추천

검색

자료유형: 학술저널

저자정보: Yazilitas, Dogan (Department of Medical Oncology, Ankara Numune Education and Research Hospital) Sendur, Mehmet Ali Nahit (Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University) Karaca, Halit (Gaziosmapasa University Faculty of Medicine, Department of Medical Oncology) Ozdemir, Nuriye (Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University) Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Cancer Institute) Berk, Veli (Gaziosmapasa University Faculty of Medicine, Department of Medical Oncology) Yazici, Ozan (Department of Medical Oncology, Ankara Numune Education and Research Hospital) Ozturk, Banu (Gaziosmapasa University Faculty of Medicine, Department of Medical Oncology) Ozkan, Metin (Gaziosmapasa University Faculty of Medicine, Department of Medical Oncology) Zengin, Nurullah (Department of Medical Oncology, Ankara Numune Education and Research Hospital) Altundag, Kadri (Department of Medical Oncology, Hacettepe University Cancer Institute)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제4호

발행연도: 2015.1

수록면: 1,471 - 1,477 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Adding taxanes to adjuvant antracycline and cyclophosphamide (AC) in combination may provide significant improvement in node-positive and high risk node-negative breast cancer (BC) patients. However, the optimal dose and the role of dose-dense (DD) chemotherapy have yet to be determined. The aim of this study was to compare the efficacy of a DD paclitaxel (P)-AC combination with conventional weekly P-AC or docetaxel D-AC combinations in patients with node-positive breast cancer. Materials and Methods: Newly diagnosed 280 node-positive BC patients diagnosed from 1998 to 2013 in three clinics were retrospectively analyzed. Demographic and medical data were collected from the medical charts. Patients were categorized to 3 groups according to treatment arms: arm A, ddAC-P; arm B, weekly P and AC combination; and arm C; T and AC combination. Adjuvant trastuzumab was added for HER2-positive patients. Kaplan-Meier survival analysis was carried out for disease free survival (DFS) and overall survival (OS). The log-rank test was used to examine the statistical significance of the differences observed between the groups. Two-sided P values <0.05 were considered statistically significant. Results: Of the total of 280 patients, 101 were in arm A, 114 in arm B and 65 in arm C.The median ages were 49, 50 and 46, respectively (p=0.11). Median follow-up was 39 (3-193) months. Stage, lymphovascular and perineural invasion, receptor patern, and menopausal status were similar in the 3 treatment arms, but HER2 positivity was significantly lower in arm A, compared to arms B and C (25.7%, 53.1%, 41.5% in arms A, B and C, respectively; p<0.001). Also grade 3 tumors were significantly less frequent in treatment arm A compared to arm B and C (27.3%, 56.8% and 49.2%, respectively, p=0.01). Afterunivariate and multivariate analysis were performed, 3-year DFS rates were 89%, 81%, and 75%, respectively (p=0.12) and three year OS rates were 96.6%, 89%, and 75% (p=0.62). Conclusions: In this study, no significant difference was found between adjuvant dose dense and conventional taxane treatment regimens.

#Breast cancer #taxanes #adjuvant chemotherapy #docetaxel #paclitaxel #dose-dense chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!